Neuropsychiatric adverse events associated with glucagon-like peptide-1 receptor agonists
Individual response varies based on baseline GH status, age, and protocol consistency
SURMOUNT-1 data show meaningful weight loss at all three maintenance dose tiers: approximately 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg
Their anti-Alzheimer's disease effects are achieved through cholinesterase enzyme inhibition, antihyperglycemic effects through the inhibition of -glucosidase and -amylase enzymes, neuroprotective effects by inhibiting monoamine oxidase type B, and anti-inflammatory effects via the inhibition of cyclooxygenase and lipoxygenase enzymes (Seker et al
After one injection, he developed a painful, unrelenting erection that lasted 22 hours a urological emergency called priapism, caused by the same pathway responsible for the drugs libido effect
DLE acknowledges the support of grants from the Welbio-FNRS (WELBIO-CR-2019C-04), Belgium